Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, et al. (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26: 3552-3559.
Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, et al. (1994) Galectins: a family of animal beta-galactoside-binding lectins. Cell 76: 597-598.
Thijssen VL, Rabinovich GA, Griffioen AW (2013) Vascular galectins: regulators of tumor progression and targets for cancer therapy. Cytokine Growth Factor Rev 24: 547-558.
Yang RY, Rabinovich GA, Liu FT (2008) Galectins: structure, function and therapeutic potential. Expert reviews in molecular medicine 10: e17.
Rabinovich GA, Croci DO (2012) Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity 36: 322-335.
Rabinovich GA, Toscano MA (2009) Turning 'sweet' on immunity: galectinglycan interactions in immune tolerance and inflammation. Nat Rev Immunol 9: 338-352.
Barrow H, Guo X, Wandall HH, Pedersen JW, Fu B, et al. (2011) Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin Cancer Res 17: 7035-7046.
Dalotto-Moreno T, Croci DO, Cerliani JP, Martinez-Allo VC, Dergan-Dylon S, et al. (2013) Targeting galectin-1 overcomes breast cancer-associated immuno-suppression and prevents metastatic disease. Cancer Res 73: 1107-1117.
Nobumoto A, Nagahara K, Oomizu S, Katoh S, Nishi N, et al. (2008) Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. Glycobiology 18: 735-744.
Cardenas Delgado VM, Nugnes LG, Colombo LL, Troncoso MF, Fernandez MM, et al. (2011) Modulation of endothelial cell migration and angiogenesis: a novel function for the "tandem-repeat" lectin galectin-8. FASEB J 25: 242-254.
Croci DO, Salatino M, Rubinstein N, Cerliani JP, Cavallin LE, et al. (2012) Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma. J Exp Med 209: 1985-2000.
Laderach DJ, Gentilini LD, Giribaldi L, Delgado VC, Nugnes L, et al. (2013) A Unique Galectin Signature in Human Prostate Cancer Progression Suggests Galectin-1 as a Key Target for Treatment of Advanced Disease. Cancer Res 73: 86-96.
Thijssen VL, Postel R, Brandwijk RJ, Dings RP, Nesmelova I, et al. (2006) Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A 103: 15975-15980.
Thijssen VL, Barkan B, Shoji H, Aries IM, Mathieu V, et al. (2010) Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res 70: 6216-6224.
Szoke T, Kayser K, Trojan I, Kayser G, Furak J, et al. (2007) The role of microvascularization and growth/adhesion-regulatory lectins in the prognosis of non-small cell lung cancer in stage II. Eur J Cardiothorac Surg 31: 783-787.
Szoke T, Kayser K, Baumhakel JD, Trojan I, Furak J, et al. (2005) Prognostic significance of endogenous adhesion/growth-regulatory lectins in lung cancer. Oncology 69: 167-174.
Fritz P, Seizer-Schmidt R, Murdter TE, Kroemer HK, Aulitzky W, et al. (1999) Ligands for Viscum album agglutinin and galectin-1 in human lung cancer: is there any prognostic relevance? Acta Histochem 101: 239-253.
Kuo PL, Hung JY, Huang SK, Chou SH, Cheng DE, et al. (2011) Lung cancer-derived galectin-1 mediates dendritic cell anergy through inhibitor of DNA binding 3/IL-10 signaling pathway. J Immunol 186: 1521-1530.
Chung LY, Tang SJ, Sun GH, Chou TY, Yeh TS, et al. (2012) Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK and cyclooxygenase-2. Clin Cancer Res 18: 4037-4047.
Hayashi T, Saito T, Fujimura T, Hara K, Takamochi K, et al. (2013) Galectin-4, a novel predictor for lymph node metastasis in lung adenocarcinoma. PLoS One 8: e81883.
Dingemans AM, van den Boogaart V, Vosse BA, van Suylen RJ, Griffioen AW, et al. (2010) Integrin expression profiling identifies integrin alpha5 and beta1 as prognostic factors in early stage non-small cell lung cancer. Mol Cancer 9: 152.
Thijssen VL, Hulsmans S, Griffioen AW (2008) The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells. Am J Pathol 172: 545-553.
Bonett DG, Price RM (2002) Statistical inference for a linear function of medians: confidence intervals, hypothesis testing, and sample size requirements. Psychol Methods 7: 370-383.
Spitzenberger F, Graessler J, Schroeder HE (2001) Molecular and functional characterization of galectin 9 mRNA isoforms in porcine and human cells and tissues. Biochimie 83: 851-862.
Heusschen R, Schulkens IA, van Beijnum J, Griffioen AW, Thijssen VL (2014) Endothelial LGALS9 splice variant expression in endothelial cell biology and angiogenesis. Biochim Biophys Acta 1842: 284-292.
Uhlen M, Bjorling E, Agaton C, Szigyarto CA, Amini B, et al. (2005) A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 4: 1920-1932.
Lahm H, Andre S, Hoeflich A, Fischer JR, Sordat B, et al. (2001) Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. J Cancer Res Clin Oncol 127: 375-386.
Sanchez-Ruderisch H, Detjen KM, Welzel M, Andre S, Fischer C, et al. (2011) Galectin-1 sensitizes carcinoma cells to anoikis via the fibronectin receptor alpha(5)beta(1)-integrin. Cell Death Differ 18: 806-816.
van den Brule F, Califice S, Castronovo V (2004) Expression of galectins in cancer: a critical review. Glycoconj J 19: 537-542.
Kosacka M, Piesiak P, Kowal A, Gołecki M, Jankowska R (2011) Galectin-3 and cyclin D1 expression in non-small cell lung cancer. J Exp Clin Cancer Res 30: 101.
Jeong SH, Lee HW, Han JH, Kang SY, Choi JH, et al. (2008) Low expression of Bax predicts poor prognosis in resected non-small cell lung cancer patients with non-squamous histology. Jpn J Clin Oncol 38: 661-669.
Mathieu A, Saal I, Vuckovic A, Ransy V, Vereerstraten P, et al. (2005) Nuclear galectin-3 expression is an independent predictive factor of recurrence for adenocarcinoma and squamous cell carcinoma of the lung. Mod Pathol 18: 1264-1271.
Kageshita T, Kashio Y, Yamauchi A, Seki M, Abedin MJ, et al. (2002) Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int J Cancer 99: 809-816.
Yamauchi A, Kontani K, Kihara M, Nishi N, Yokomise H, et al. (2006) Galectin-9, a novel prognostic factor with antimetastatic potential in breast cancer. Breast J 12: S196-S200.
Zhang ZY, Dong JH, Chen YW, Wang XQ, Li CH, et al. (2012) Galectin-9 acts as a prognostic factor with antimetastatic potential in hepatocellular carcinoma. Asian Pac J Cancer Prev 13: 2503-2509.
Jiang J, Jin MS, Kong F, Cao D, Ma HX, et al. (2013) Decreased galectin-9 and increased tim-3 expression are related to poor prognosis in gastric cancer. PLoS One 8: e81799.
Earl LA, Bi S, Baum LG (2011) Galectin multimerization and lattice formation are regulated by linker region structure. Glycobiology 21: 6-12.
Heusschen R, Freitag N, Tirado-González I, Barrientos G, Moschansky P, et al. (2013) Profiling Lgals9 splice variant expression at the fetal-maternal interface: implications in normal and pathological human pregnancy. Biol Reprod 88: 22.
Zhang F, Zheng M, Qu Y, Li J, Ji J, et al. (2009) Different roles of galectin-9 isoforms in modulating E-selectin expression and adhesion function in LoVo colon carcinoma cells. Mol Biol Rep 36: 823-830.
Kasamatsu A, Uzawa K, Nakashima D, Koike H, Shiiba M, et al. (2005) Galectin-9 as a regulator of cellular adhesion in human oral squamous cell carcinoma cell lines. Int J Mol Med 16: 269-273.
Irie A, Yamauchi A, Kontani K, Kihara M, Liu D, et al. (2005) Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res 11: 2962-2968.
Wiersma VR, de Bruyn M, Helfrich W, Bremer E (2011) Therapeutic potential of Galectin-9 in human disease. Med Res Rev.
Liang M, Ueno M, Oomizu S, Arikawa T, Shinonaga R, et al. (2008) Galectin-9 expression links to malignant potential of cervical squamous cell carcinoma. J Cancer Res Clin Oncol 134: 899-907.
Heusschen R, Griffioen AW, Thijssen VL (2013) Galectin-9 in tumor biology: a jack of multiple trades. Biochim Biophys Acta 1836: 177-185.
Chabot S, Kashio Y, Seki M, Shirato Y, Nakamura K, et al. (2002) Regulation of galectin-9 expression and release in Jurkat T cell line cells. Glycobiology 12: 111-118.
Hirashima M (2000) Ecalectin/galectin-9, a novel eosinophil chemoattractant: its function and production. Int Arch Allergy Immunol 122 Suppl 1: 6-9.
Keryer-Bibens C, Pioche-Durieu C, Villemant C, Souquère S, Nishi N, et al. (2006) Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9. BMC Cancer 6: 283.
Klibi J, Niki T, Riedel A, Pioche-Durieu C, Souquere S, et al. (2009) Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood 113: 1957-1966.
